István Móra

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Raman Spectroscopy

High Throughput

Epidermal Growth Factor Receptor

Top Venues

International journal of molecular sciences

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

József Murányi, Cintia Duró, Bianka Gurbi, István Móra, Attila Varga, Krisztina Németh, József Simon, Miklós Csala, Antal Csámpai
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. International journal of molecular sciences 24 (4) (2023)
József Murányi, Cintia Duró, Bianka Gurbi, István Móra, Attila Varga, Krisztina Németh, József Simon, Miklós Csala, Antal Csámpai
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. International journal of molecular sciences 24 (4) (2023)
József Murányi, Cintia Duró, Bianka Gurbi, István Móra, Attila Varga, Krisztina Németh, József Simon, Miklós Csala, Antal Csámpai
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. International journal of molecular sciences 24 (4) (2023)
József Murányi, Cintia Duró, Bianka Gurbi, István Móra, Attila Varga, Krisztina Németh, József Simon, Miklós Csala, Antal Csámpai
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. International journal of molecular sciences 24 (4) (2023)
József Murányi, Cintia Duró, Bianka Gurbi, István Móra, Attila Varga, Krisztina Németh, József Simon, Miklós Csala, Antal Csámpai
Novel Erlotinib-Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms. International journal of molecular sciences 24 (4) (2023)
Tamás Czuczi, József Murányi, Péter Bárány, István Móra, Adina Borbély, Miklós Csala, Antal Csámpai
Synthesis and Antiproliferative Activity of Novel Imipridone-Ferrocene Hybrids with Triazole and Alkyne Linkers. Pharmaceuticals (Basel, Switzerland) 15 (4) (2022)